Clinical Trials
13
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (13 trials with phase data)β’ Click on a phase to view related trials
A Study of LM-350 in Subjects With Advanced Solid Tumours
- Conditions
- Malignant Tumors
- Interventions
- Drug: LM-350 for injection
- First Posted Date
- 2025-08-08
- Last Posted Date
- 2025-09-09
- Lead Sponsor
- LaNova Medicines Limited
- Target Recruit Count
- 55
- Registration Number
- NCT07112222
- Locations
- π¦πΊ
Peninsula and South Eastern Haematology and Oncology Group, Frankston, Victoria, Australia
A Study of LM-108 in Combination With Toripalimab in Subjects With Advanced Solid Tumours
- First Posted Date
- 2025-03-13
- Last Posted Date
- 2025-03-13
- Lead Sponsor
- LaNova Medicines Limited
- Target Recruit Count
- 84
- Registration Number
- NCT06873854
- Locations
- π¨π³
Beijing Cancer Hospital, Beijing, Beijing, China
A Study of LM-168 as a Single Agent or in Combination With Toripalimab in Subjects With Advanced Solid Tumours
- First Posted Date
- 2025-03-10
- Last Posted Date
- 2025-09-12
- Lead Sponsor
- LaNova Medicines Limited
- Target Recruit Count
- 87
- Registration Number
- NCT06868199
- Locations
- π¦πΊ
Macquarie University, Ryde, New South Wales, Australia
π¦πΊMUPharm Pty Limited trading as Macquarie University Hospital Parmarcy, Ryde, New South Wales, Australia
π¦πΊCancer Care Wollongong Pty Limited, Wollongong, New South Wales, Australia
A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours
- Conditions
- Advanced Solid Tumor
- Interventions
- Drug: Toripalimab/Tirelizumab
- First Posted Date
- 2024-11-12
- Last Posted Date
- 2025-09-25
- Lead Sponsor
- LaNova Medicines Limited
- Target Recruit Count
- 320
- Registration Number
- NCT06682780
- Locations
- π¨π³
FuDan University Shanghai Cancer Center, Shanghai, Shanghai Municipality, China
Study of LM-299 in Subjects Advanced Malignant Tumors
- First Posted Date
- 2024-10-21
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- LaNova Medicines Limited
- Target Recruit Count
- 108
- Registration Number
- NCT06650566
- Locations
- π¦πΊ
One Clinical Research, Perth, West Australia, Australia
π¨π³the first affiliated hospital of Xinxiang medical University, Xinxiang, Henan, China
π¨π³Liaocheng people's hospital, Liaocheng, Shandong, China
- Prev
- 1
- 2
- 3
- Next